Spruce Street Capital LP
Spruce Street Capital LP reported 30 US-listed holdings worth $509.7 million in its 13F for the quarter ended 30 June 2026, filed 13 August 2026. Its largest: Kiniksa Pharmaceuticals Intl (11.5%), Relay Therapeutics Inc. (11.0%) and LB Pharmaceuticals Inc. (8.8%). Against the quarter before, it opened 5 positions, added to 8, trimmed 1 and sold out of 3.
The 14 largest of its 30 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +63.9% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 5
- Inflarx NV IFRX$12.0 million
- Research Alliance Corp Iii Ord Shs Cl A RACC$5.3 million
- Zai Lab Limited ZLAB$5.3 million
- Achieve Life Sciences Inc. ACHV$4.8 million
- Jatt II Acquisition Corp. JATT$1.8 million
Added to 8
- Alkermes plc. ALKS+225,884 shares · +71%
- Kiniksa Pharmaceuticals Intl KNSA+157,007 shares · +21%
- Perspective Therapeutics Inc CATX+1.1 million shares · +41%
- Vaxcyte Inc. PCVX+60,338 shares · +25%
- Enanta Pharmaceuticals Inc. ENTA+156,133 shares · +17%
- Relmada Therapeutics Inc. RLMD+129,214 shares · +2%
- Alto Neuroscience Inc. ANRO+27,837 shares · +2%
- Savara Inc. SVRA+69,401 shares · +2%
Trimmed 1
- Dianthus Therapeutics Inc. DNTH-18,458 shares · -5%
Sold out of 3
- Centessa Pharmaceuticals PLC CNTA$19.5 million last quarter
- Kalvista Pharmaceuticals Inc. KALV$18.1 million last quarter
- Maze Therapeatics MAZE$6.0 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Kiniksa Pharmaceuticals Intl KNSA | 918.1K | $58.7 million | 11.52% | +157.0K |
| Relay Therapeutics Inc. RLAY | 3.0M | $55.8 million | 10.95% | no change |
| LB Pharmaceuticals Inc. LBRX | 1.4M | $44.7 million | 8.76% | no change |
| Relmada Therapeutics Inc. RLMD | 6.4M | $44.2 million | 8.68% | +129.2K |
| Alto Neuroscience Inc. ANRO | 1.4M | $35.7 million | 7.01% | +27.8K |
| Dianthus Therapeutics Inc. DNTH | 354.8K | $34.6 million | 6.79% | -18.5K |
| Alkermes plc. ALKS | 543.9K | $28.5 million | 5.59% | +225.9K |
| Savara Inc. SVRA | 3.5M | $21.3 million | 4.17% | +69.4K |
| Vaxcyte Inc. PCVX | 306.0K | $17.8 million | 3.49% | +60.3K |
| Enliven Therapeutics Inc. ELVN | 329.0K | $16.7 million | 3.28% | no change |
| Enanta Pharmaceuticals Inc. ENTA | 1.1M | $15.9 million | 3.11% | +156.1K |
| Perspective Therapeutics Inc CATX | 3.7M | $12.6 million | 2.47% | +1.1M |
| Inflarx NV IFRX | 5.4M | $12.0 million | 2.35% | new |
| Surrozen Inc. SRZN | 432.0K | $11.2 million | 2.20% | no change |
| Alumis Inc. ALMS | 392.6K | $11.0 million | 2.17% | no change |
| Century Therapeutics Inc. IPSC | 4.1M | $9.9 million | 1.95% | no change |
| Minerva Neurosciences Inc. NERV | 1.7M | $9.2 million | 1.80% | no change |
| Sab Biotherapeutics Inc. SABS | 2.2M | $8.6 million | 1.68% | no change |
| AN2 Therapeutics Inc. ANTX | 1.7M | $8.0 million | 1.58% | no change |
| Erasca Inc. ERAS | 422.5K | $7.7 million | 1.52% | no change |
| Inhibikase Therapeutics Inc. IKT | 3.6M | $7.3 million | 1.43% | no change |
| Research Alliance Corp Iii Ord Shs Cl A RACC | 500.0K | $5.3 million | 1.05% | new |
| Helix Acquisition Corp. III HLXC | 500.0K | $5.3 million | 1.04% | no change |
| Zai Lab Limited ZLAB | 279.1K | $5.3 million | 1.04% | new |
| Achieve Life Sciences Inc. ACHV | 736.6K | $4.8 million | 0.94% | new |
| Lexeo Therapeutics Inc. LXEO | 928.6K | $4.3 million | 0.85% | no change |
| Alector Inc. ALEC | 2.1M | $4.2 million | 0.83% | no change |
| Athira Pharma Inc. LONA | 393.7K | $3.6 million | 0.71% | no change |
| Corvus Pharmaceuticals Inc. CRVS | 231.6K | $3.5 million | 0.68% | no change |
| Jatt II Acquisition Corp. JATT | 160.0K | $1.8 million | 0.36% | new |